Table 5 |
|||
|
Relationship between antibiotic use and intensive care unit mortality in univariate analysis |
|||
|
Survivors (n = 60) |
Non-survivors (n = 54) |
p value |
|
|
|
|||
|
Antibiotic treatment |
38 (63) |
47 (87) |
<0.003a |
|
Duration of antibiotic treatment, days |
7 ± 8 |
10 ± 10 |
0.197 |
|
Glycopeptide use |
9 (15) |
11 (20) |
0.225 |
|
Duration, days |
2 ± 3 |
1 ± 3 |
0.399 |
|
Extended-spectrum penicillin use |
34 (56) |
38 (70) |
0.099 |
|
Duration, days |
8 ± 8 |
7 ± 8 |
0.710 |
|
Fluoroquinolone use |
22 (36) |
24 (44) |
0.336 |
|
Duration, days |
6 ± 6 |
5 ± 4 |
0.913 |
|
Extended-spectrum cephalosporin use |
3 (5) |
16 (29) |
0.001b |
|
Duration, days |
1 ± 3 |
2 ± 5 |
0.002 |
|
Carbapenem use |
5 (8) |
7 (12) |
0.306 |
|
Duration, days |
3 ± 3 |
4 ± 1 |
0.428 |
|
Aminoglycoside use |
10 (16) |
15 (27) |
0.233 |
|
Duration, days |
2 ± 5 |
2 ± 4 |
0.154 |
|
Metronidazole use |
4 (7) |
3 (6) |
0.559 |
|
Duration, days |
0.4 ± 2 |
0.3 ± 2 |
0.785 |
|
|
|||
|
Data are presented as mean ± standard deviation or number (percentage). Odds ratio (95% confidence interval) = a3.8 (1.5 to 10) and b7.3 (1.9 to 26.9). |
|||
|
Nseir et al. Critical Care 2006 10:R143 doi:10.1186/cc5063 |
|||
